Nuvalent (NUVL) Other Accumulated Expenses (2023 - 2024)
Nuvalent (NUVL) posted Other Accumulated Expenses of $1.3 million for Q4 2024, down 21.37% on a QoQ basis from $1.6 million in Q4 2023, and down 21.37% year-over-year from $1.6 million in Q1 2024.
Nuvalent (NUVL) Other Accumulated Expenses (2023 - 2024) Analysis & Trends
Nuvalent's Other Accumulated Expenses history runs 2 years deep, the most recent figure standing at $1.3 million for Q4 2024.
- Quarterly Other Accumulated Expenses fell 21.37% year-over-year to $1.3 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $1.3 million (down 21.37% YoY) and the FY2024 annual result came in at $1.3 million, down 21.37% from the prior year.
- Other Accumulated Expenses was $1.3 million for Q4 2024 at Nuvalent, down from $1.6 million in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $1.6 million in Q4 2023 and bottomed at $1.3 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.90 Bn | 61.14 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.46 Bn | 37.46 Bn | - |
| 10 | Nuvalent | 9.75 Bn | 9.75 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1.28 Mn |
| Dec 31, 2023 | 1.62 Mn |